Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study

医学 免疫抑制 无容量 内科学 临床终点 人口 肾癌 临床试验 肿瘤科 肌酐 癌症 免疫疗法 环境卫生
作者
Robert P. Carroll,Michael Boyer,Val Gebski,Bronwyn Hockley,Julie Johnston,Svjetlana Kireta,Hsiang Tan,Anne E. Taylor,Kate Wyburn,John Zalcberg
出处
期刊:Lancet Oncology [Elsevier]
卷期号:23 (8): 1078-1086 被引量:38
标识
DOI:10.1016/s1470-2045(22)00368-0
摘要

Background Most kidney transplant recipients with cancer stop or reduce immunosuppressive therapy before starting treatment with an immune checkpoint inhibitor, and approximately 40% of such patients will develop allograft rejection. Isolated immunosuppression reduction might be associated with organ rejection. Whether immunosuppression manipulation, immune checkpoint inhibition, or both, induce organ rejection is difficult to ascertain. The aim of this study was to examine the risk of allograft rejection with immune checkpoint inhibitor exposure when baseline immunosuppression was left unchanged. Methods We conducted a multicentre, single-arm, phase 1 study in three hospitals in Australia. Kidney transplant recipients aged 18 years or older with incurable, locally advanced cancer or defined metastatic solid tumours were eligible if they had a creatinine concentration of less than 180 mmol/L, no or low concentrations of donor-specific HLA antibodies, and an Eastern Cooperative Oncology Group status of 0–2. Patients received standard doses of nivolumab (3 mg/kg intravenously every 14 days for five cycles, then 480 mg every 28 days for up to 2 years). The primary endpoint was the proportion of patients with irretrievable allograft rejection and no evidence of tumour response. Primary outcome analyses and safety analyses were done in the modified intention-to-treat population. This trial is registered with the Australian and New Zealand Clinical Trials Register, ANZCTR12617000741381, and is completed. Findings Between May 31, 2017, and Aug 6, 2021, 22 kidney transplant recipients with various solid tumours were screened and enrolled, four of whom chose not to proceed in the study and one of whom had unexpected disease progression. 17 patients (six [35%] women and 11 [65%] men; median age 67 years [IQR 59–71]) were allocated treatment with nivolumab and were included in the analyses. The trial was then stopped due to ongoing difficulties with running clinical trials during COVID-19 health restrictions. Patients were treated with a median of three infusions (IQR 2–10) and median follow-up was 28 months (IQR 16–34). No patients had irretrievable allograft rejection without evidence of tumour response. There were no treatment-related deaths or treatment-related serious adverse events. The most common grade 3 or grade 4 adverse events were decreased lymphocyte count in four (24%) patients, fever or infection in four (24%) patients, decreased haemoglobin in three (18%) patients, and increased creatinine in three (18%) patients. Interpretation Maintaining baseline immunosuppression before treatment with an immune checkpoint inhibitor in kidney transplant recipients might not affect expected efficacy and might reduce the risk of allograft rejection mediated by immune checkpoint inhibitors. Funding Bristol Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
杨然发布了新的文献求助10
1秒前
2秒前
圆圆圆完成签到 ,获得积分10
4秒前
冷酷云朵发布了新的文献求助10
4秒前
4秒前
山月完成签到 ,获得积分10
4秒前
碧蓝的蜻蜓完成签到 ,获得积分10
7秒前
8秒前
平淡的谷秋完成签到 ,获得积分10
9秒前
XYZ发布了新的文献求助10
10秒前
杨然完成签到,获得积分10
11秒前
12秒前
ww完成签到,获得积分10
12秒前
Ldq发布了新的文献求助10
12秒前
Quanquan完成签到 ,获得积分10
12秒前
很酷的妞子完成签到 ,获得积分10
13秒前
ll完成签到 ,获得积分10
13秒前
小黄鸭发布了新的文献求助10
13秒前
烟花应助羊青丝采纳,获得10
14秒前
14秒前
清爽聋五发布了新的文献求助10
15秒前
雪落你看不见完成签到,获得积分10
16秒前
思源应助眼睛大的冰岚采纳,获得10
16秒前
BBQ发布了新的文献求助30
17秒前
syt发布了新的文献求助10
20秒前
25秒前
眼睛大的冰岚完成签到,获得积分10
25秒前
26秒前
所所应助科研通管家采纳,获得10
27秒前
充电宝应助科研通管家采纳,获得10
27秒前
思源应助科研通管家采纳,获得10
27秒前
英姑应助科研通管家采纳,获得10
27秒前
科研通AI2S应助科研通管家采纳,获得10
27秒前
科目三应助科研通管家采纳,获得10
27秒前
CipherSage应助科研通管家采纳,获得10
28秒前
科研通AI2S应助科研通管家采纳,获得10
28秒前
Henry应助科研通管家采纳,获得200
28秒前
wking应助科研通管家采纳,获得20
28秒前
28秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137545
求助须知:如何正确求助?哪些是违规求助? 2788520
关于积分的说明 7787226
捐赠科研通 2444861
什么是DOI,文献DOI怎么找? 1300083
科研通“疑难数据库(出版商)”最低求助积分说明 625796
版权声明 601023